Tamara van Donge

Kidney injury biomarkers in pediatrics 187 9 37. Wheeler DS, Devarajan P, Ma Q, et al. Serum neutrophil gelatinase-associated lipocalin (NGAL) as a marker of acute kidney injury in critically ill children with septic shock. Critical care medicine. 2008;36(4):1297. 38. Argyropoulos CP, Chen SS, Ng Y-H, et al. Rediscovering beta-2 microglobulin as a biomarker across the spectrum of kidney diseases. Frontiers in Medicine. 2017;4:73. 39. Peterson PA, Evrin P-E, Berggård I. Differentiation of glomerular, tubular, and normal proteinuria: determinations of urinary excretion of β 2-microglobulin, albumin, and total protein. The Journal of clinical investigation. 1969;48(7):1189-1198. 40. Lopez-Giacoman S, Madero M. Biomarkers in chronic kidney disease, from kidney function to kidney damage. World journal of nephrology. 2015;4(1):57. 41. Cullen MR, Murray PT, Fitzgibbon MC. Establishment of a reference interval for urinary neutrophil gelatinase-associated lipocalin. Annals of Clinical Biochemistry. 2012;49(2):190-193. 42. Gan J, Zhou X. Comparison of urine neutrophil gelatinase-associated lipocalin and interleukin-18 in prediction of acute kidney injury in adults. Medicine. 2018;97(39). 43. Kornhauser C, Dubey L-A, Garay M-E, Pérez-Luque E-L, Malacara J-M, Vargas-Origel A. Serum and urinary insulin-like growth factor-1 and tumor necrosis factor in neonates with and without acute renal failure. Pediatric Nephrology. 2002;17(5):332-336. 44. Portilla D, Dent C, Sugaya T, et al. Liver fatty acid-binding protein as a biomarker of acute kidney injury after cardiac surgery. Kidney international. 2008;73(4):465-472. 45. Kaddourah A, Goldstein SL, Basu R, et al. Novel urinary tubular injury markers reveal an evidence of underlying kidney injury in children with reduced left ventricular systolic function: a pilot study. Pediatric Nephrology. 2016;31(10):1637-1645. 46. Wilbaux M, Fuchs A, Samardzic J, et al. Pharmacometric approaches to personalize use of primarily renally eliminated antibiotics in preterm and term neonates. The Journal of Clinical Pharmacology. 2016;56(8):909-935. 47. Nayak-Rao S. Aminoglycoside use in renal failure. Indian journal of nephrology. 2010;20(3):121. 48. Amur S, LaVange L, Zineh I, Buckman‐Garner S, Woodcock J. Biomarker qualification: toward a multiple stakeholder framework for biomarker development, regulatory acceptance, and utilization. Clinical Pharmacology & Therapeutics. 2015;98(1):34-46. 49. Woodcock J, Buckman S, Goodsaid F, Walton MK, Zineh I. Qualifying biomarkers for use in drug development: a US Food and Drug Administration overview. Expert opinion on medical diagnostics. 2011;5(5):369-374. 50. Dieterle F, Sistare F, Goodsaid F, et al. Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium. Nature biotechnology. 2010;28(5):455. 51. FDA. Guidance for industry and FDA staff: qualification process for drug development tools. Center for Drug Evaluation and Research (CDER). Silver Spring, MD: Office of Communications, Division of Drug Information. 2014.